{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T13:22:34Z","timestamp":1768656154378,"version":"3.49.0"},"reference-count":23,"publisher":"Japan Surgical Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Surg Case Rep"],"published-print":{"date-parts":[[2026]]},"DOI":"10.70352\/scrj.cr.25-0622","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:09:32Z","timestamp":1768342172000},"page":"n\/a","source":"Crossref","is-referenced-by-count":0,"title":["Conversion Surgery for Advanced Gastric Cancer with Para-Aortic Lymph Node Metastases Following Treatment with Capecitabine, Oxaliplatin, and Pembrolizumab: A Case Report"],"prefix":"10.70352","volume":"12","author":[{"given":"Takuya","family":"Ono","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Waki","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masumi","family":"Takamoto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Tokuda","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Ehime Prefectural Niihama Hospital, Niihama, Ehime, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"51119","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687\u201397.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2022; 23: 234\u201347.","DOI":"10.1016\/S1470-2045(21)00692-6"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate649): a randomised, open-label, phase 3 trial. Lancet 2021; 398: 27\u201340.","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Rha SY, Oh DY, Ya\u00f1ez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2023; 24: 1181\u201395.","DOI":"10.1016\/S1470-2045(23)00515-6"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer 2023; 26: 1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2020; 38: 1\u201310.","DOI":"10.1200\/JCO.19.02105"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet 2018; 392: 123\u201333.","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Yoshida K, Yamaguchi K, Okumura N, et al. The roles of surgical oncologists in the new era: minimally invasive surgery for early gastric cancer and adjuvant surgery for metastatic gastric cancer. Pathobiology 2011; 78: 343\u201352.","DOI":"10.1159\/000328197"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Suzuki T, Tanabe K, Taomoto J, et al. Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett 2010; 1: 743\u20137.","DOI":"10.3892\/ol_00000130"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yoshida K, Yamaguchi K, Okumura N, et al. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer 2016; 19: 329\u201338.","DOI":"10.1007\/s10120-015-0575-z"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yoshida K, Yasufuku I, Terashima M, et al. International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). Ann Gastroenterol Surg 2021; 6: 227\u201340.","DOI":"10.1002\/ags3.12515"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 2014; 101: 653\u201360.","DOI":"10.1002\/bjs.9484"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Yu P, Zhang Y, Ye Z, et al. Treatment of synchronous liver metastases from gastric cancer: a single-center study. Cancer Manag Res 2020; 12: 7905\u201311.","DOI":"10.2147\/CMAR.S261353"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann Oncol 2015; 26: 141\u20138.","DOI":"10.1093\/annonc\/mdu472"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): a randomised, open-label, phase 3 trial. Lancet Oncol 2020; 21: 1045\u201356.","DOI":"10.1016\/S1470-2045(20)30315-6"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kano Y, Ichikawa H, Hanyu T, et al. Conversion surgery for stage IV gastric cancer: a multicenter retrospective study. BMC Surg 2022; 22: 428.","DOI":"10.1186\/s12893-022-01874-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Huang X, Chen X, Chen J, et al. Immune checkpoint inhibitors combined with chemotherapy in conversion therapy for stage IV gastric cancer: a multicenter retrospective cohort study. Cancer Immunol Immunother 2025; 74: 302.","DOI":"10.1007\/s00262-025-04161-6"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Nishino M, Yoshikawa T, Shoji H, et al. Unexpectedly high incidence of immune-related adverse events in gastric cancer patients who received conversion surgery after nivolumab-including chemotherapy. Ann Gastroenterol Surg 2025: ags3.70103.","DOI":"10.1002\/ags3.70103"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1\/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric\/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol 2019; 30: 250\u20138.","DOI":"10.1093\/annonc\/mdy540"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer. N Engl J Med 2008; 359: 453\u201362.","DOI":"10.1056\/NEJMoa0707035"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Al-Batran SE, Homann N, Pauligk C, et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: the AIO-FLOT3 trial. JAMA Oncol 2017; 3: 1237\u201344.","DOI":"10.1001\/jamaoncol.2017.0515"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Al-Batran S, Goetze T, Mueller D, et al. The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO\/CAO-V\/CAOGI. BMC Cancer 2017; 17: 893.","DOI":"10.1186\/s12885-017-3918-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Kita R, Yasufuku I, Takahashi N, et al. Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study). Jpn J Clin Oncol 2025; 55: 304\u201310.","DOI":"10.1093\/jjco\/hyae174"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0622\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T04:44:53Z","timestamp":1768625093000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/scrj\/12\/1\/12_cr.25-0622\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.70352\/scrj.cr.25-0622","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"article-number":"cr.25-0622"}}